Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors (IMMUNOPARP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04675320
Recruitment Status : Recruiting
First Posted : December 19, 2020
Last Update Posted : December 19, 2020
Sponsor:
Information provided by (Responsible Party):
Centre Georges Francois Leclerc

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study concerns the creation of a biological collection (blood samples) in patients with Epithelial Ovarian Cancerin in order to describe the immune response with PARP inhibitors.

Condition or disease Intervention/treatment
Ovarian Cancer Other: blood sample

Detailed Description:
The aim is to assess the impact of anti-PARP on peripheral immune populations and the amount of DNA circulating; to correlate these data with tumor infiltration, with the initial clinical characteristics and with the clinical course; compare the immunogenic effect of different anti-PARPs.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
Actual Study Start Date : July 7, 2020
Estimated Primary Completion Date : July 7, 2021
Estimated Study Completion Date : July 7, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Mutated BRCA epithelial ovarian cancer Other: blood sample
Olaparib
Recurrent epithelial ovarian cancer Other: blood sample
Niraparib or Olaparib


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. blood analysis [ Time Frame: up to 6 months ]
    immunophenotyping,plasma library and PBMC bank.


Biospecimen Retention:   Samples With DNA
blood sample

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
cohorte 1 : patients with Mutated BRCA epithelial ovarian cancer - interviewed by Olaparib cohorte 2 : patients with Recurrent epithelial ovarian cancer - maintained with Niraparib or Olaparib
Criteria

Inclusion Criteria:

  • Epithelial Ovarian Cancer
  • Eligible for treatment by anti-PARP treatment with Olaparib or Niraparib
  • informed consent signed

Exclusion Criteria:

  • Non Epithelial Ovarian Cancer
  • Current or previous use of an immunosuppressive drug 14 days before inclusion
  • Pregnant or breastfeeding woman.
  • VIH et/ou VHB et/ou VHC positive
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04675320


Contacts
Layout table for location contacts
Contact: Jean-David FUMET 03 80 73 75 00 jdfumet@cgfl.fr

Locations
Layout table for location information
France
CHRU Jean Minjoz Recruiting
Besançon, France, 25000
Principal Investigator: Fernando BAZAN         
Sub-Investigator: Elsa KALBACHER         
Sub-Investigator: Laura MANSI         
Sub-Investigator: Guillaume MEYNARD         
Centre Georges Francois Leclerc Recruiting
Dijon, France, 21000
Principal Investigator: Jean David FUMET         
Sub-Investigator: Isabelle DESOULIN         
Sub-Investigator: Sylvia ILIE         
Sub-Investigator: Audrey HENNEQUIN         
Sub-Investigator: Courèche KADERBHAI         
Sub-Investigator: Alice HERVIEU         
Sub-Investigator: Leila BENGRINE         
Sub-Investigator: Laure FAVIER         
Sponsors and Collaborators
Centre Georges Francois Leclerc
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Centre Georges Francois Leclerc
ClinicalTrials.gov Identifier: NCT04675320    
Other Study ID Numbers: 2020-A00036-33
First Posted: December 19, 2020    Key Record Dates
Last Update Posted: December 19, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Georges Francois Leclerc:
PARP Inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
 Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type